Finance entity
Every one of those 2 sits in a single category, markets. TERN-701 is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. At 8, the average consequence score sits above the same-window beat average of 6.3.
Last mentioned: Mar 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, markets. TERN-701 is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. At 8, the average consequence score sits above the same-window beat average of 6.3. Each story carries 2 original sources on average, compared with 2.6 for the broader beat in this window. Keytruda appears in 2 tracked Finance stories from March 25, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 84 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Keytruda. Shared-story counts are live from our verified record — not editorial picks.
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a high-potential leukemia treatment. The deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its top-selling drug, Keytruda.
Merck has agreed to acquire Terns Pharmaceuticals for $6.7 billion in cash to bolster its oncology pipeline ahead of the 2028 patent expiration for its blockbuster drug, Keytruda. The deal centers on TERN-701, a promising leukemia treatment that positions Merck to compete directly with established players like Novartis.
Keytruda is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
